Featured
News
RECOVERY: Randomised Evaluation of COVID-19 Therapy
Led by ERGO's Peter Horby, this national clinical trial aims to identify treatments that may be beneficial for adults hospitalised with confirmed COVID-19. The trial is being conducted in over 130 NHS hospitals across the UK. Adult patients who have been admitted to hospital with COVID-19 are being invited to take part, and more information can be found at https://www.recoverytrial.net/.
Watch Peter discussing the trial on our Talks and Videos page.
Articles
Evaluation of the efficacy and safety of intravenous remdesivir in adult patients with severe COVID-19: study protocol for a phase 3 randomized, double-blind, placebo-controlled, multicentre trial
Background Coronavirus disease 2019 (COVID-19), caused by a novel corinavirus (later named SARS-CoV-2 virus), was fistly reported in Wuhan, Hubei Province, China towards the end of 2019. Large-scale spread within ...
Global outbreak research: harmony not hegemony
To make clinical and biological observations within a timeframe that is likely to benefit patients during disease outbreaks, coordination of global research must match the speed of spread of novel ...
Scope, quality, and inclusivity of clinical guidelines produced early in the covid-19 pandemic: rapid review
Conclusions: Guidelines available early in the covid-19 pandemic had methodological weaknesses and neglected vulnerable groups such as older people. A framework for development of clinical guidelines during public ...
Features of 20 133 UK patients in hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: prospective observational cohort study
The largest prospective observational study to date provides a comprehensive picture of the patients’ outcomes and characteristics that have been hospitalised in the UK with covid-19. Age, gender, obesity and ...
Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial
The Lancet - 29th April 2020 No specific antiviral drug has been proven effective for treatment of patients with severe coronavirus disease 2019 (COVID-19). Remdesivir (GS-5734), a nucleoside analogue prodrug, ...
Dexamethasone reduces mortality in hospitalised patients with respiratory complications of COVID-19
Professor Peter Horby and Professor Martin Landray, chief investigators of the Randomised Evaluation of COVid-19 thERapY (RECOVERY) trial, said: In March this year, RECOVERY was established as a randomised clinical trial to test a range of potential treatments for COVID-19, ... Read more